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Patients and methods: Forty-six brain tumor patients were examined by diffusion MRI before and
3 weeks after initiation of chemo- and/or radiotherapy. Images were co-registered to pretherapy
scans, and tumor volumes with signiﬁcant changes in apparent diffusion coefﬁcient values were spa-
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442 B.A.M. Dessouky et al.their correlation with the standard clinico-radiologic response criteria and overall survival of the
two response groups was determined.
Results: Of the analyzed 46 brain tumors, 21 tumors were responding and 25 were stable/non-
responding. At 3 weeks after initiation of therapy, the percentage of tumor volume with signiﬁcant
increase in diffusion (VR; red voxels) was the strongest predictor of treatment response than the
changes in whole-tumor volume and mean ADC values determined at the same time point as com-
pared to their pretherapy values. VR threshold of 14.5% at 3 weeks had sensitivity, speciﬁcity, posi-
tive and negative predictive values of 100% for all for differentiating responding from stable/non-
responding tumors. Overall survival in stable/non-responding group was shorter than in the
responding group (8.7 versus 35.6 months; **P< 0.001).
Conclusion: The use of fDM provided an early and direct surrogate marker for predicting treat-
ment response and patient survival in patients with malignant brain tumor.
 2010 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Although most brain tumors, especially the malignant variety,
remain difﬁcult to cure, there are promising novel therapies
and drug delivery systems that are under active investigation
(1). One of the greatest challenges in developing effective ther-
apy for brain tumors is the lack of speciﬁc markers to directly
and accurately assess anti-tumor effect early and non-inva-
sively (2). Further challenge lies in the fact that early treatment
response can be transient and may not necessarily translate
into long-term response or a favorable clinical outcome (3).
In addition, due to the short life span of these patients there
may be a small window of opportunity to assess therapeutic
efﬁcacy so that an early biomarker of tumor response might
prevent continued treatment of the patient with a high-cost
and/or high-risk regimen with no demonstrated individual
beneﬁt and rapidly switch the patient to another therapy that
may increase treatment response and patient survival before
there is widespread damage to the normal brain (4,5).
Conventional imaging techniques such as contrast en-
hanced magnetic resonance imaging and contrast enhanced
computed tomography are currently used to assess and moni-
tor radiation and chemotherapy response for brain tumors.
These imaging modalities relied upon identifying morphologi-
cal changes in tumor size weeks to months after the conclusion
of a therapeutic protocol to deﬁne response or progression (6).
These changes in gross tumor size signiﬁcantly lag behind the
biological and molecular changes that occur early in respond-
ers (7,8). Due to tumor heterogeneity, it is unlikely that all can-
cers of a particular type will respond to a speciﬁc therapy,
besides that, with the development anti-angiogenesis agents,
certain tumors would not reduce in size emphasizing the need
for a reliable and early predictor marker of treatment outcome
that can be used to guide therapy and to improve survival in
patients in malignant brain tumors (8,9).
The ability of diffusion magnetic resonance imaging
(DW-MRI) to predict tumor response has been reported (5).
Particular advantages of DW-MRI are that it is non-invasive
and does not require intravenous contrast media. It measures
the random (Brownian) motion of water. Increased diffusion
of water molecules (measured as an increase in the apparent
diffusion coefﬁcient [ADC]) occurs shortly after a successful
treatment, and correlates with the breakdown of cellular mem-
branes and reduction in cell density that both precede changes
in tumor size (10–12). The change in cellularity may lead toheterogeneous changes in the underlying tissue morphology
(e.g. ratio of intra- to extra-cellular water) resulting in spatially
varying changes in tumor apparent diffusion coefﬁcient (ADC)
values (13,14).
Quantiﬁcation of diffusion changes has evolved from the
mean change in ADC to a voxel-by-voxel approach termed
the functional diffusion map (fDM) (15–20). Functional diffu-
sion mapping (fDM), was recently proposed as an MRI imag-
ing biomarker for quantifying early brain tumor response to
therapy. This approach quantiﬁes local apparent diffusion
coefﬁcient (ADC) changes in tumors using a voxel-based anal-
ysis implemented by rigid registration of the patient’s data be-
tween interval exams (18–23).
The purpose of the current studywas to evaluate the ability of
functional diffusion mapping (fDM) as a validated imaging bio-
marker for early and direct prediction of therapeutic response
and survival in patients with primary malignant brain tumors.
2. Patients and methods
2.1. Patient population
Between October 2005 and October 2009, 46 consecutive pa-
tients with pathologically proven primary malignant brain tu-
mors who were scheduled to receive radiation therapy,
chemotherapy or combination therapy were included on our
prospective study. These patients were serially imaged using
diffusion-weighted magnetic resonance imaging (DW-MRI) 1
week before and 3 weeks after initiation of therapy.
2.2. Protocol of diffusion-weighted MR imaging
Magnetic resonance imaging was performed on 1.5-T units
(General Electric Medical Systems, Milwaukee, WI) using a
standard head coil. Each patient underwent baseline MR imag-
ing 1 week before initiation of therapy consisting of precontrast
T2-weighted, ﬂuid-attenuated inversion-recovery, and gadolin-
ium-enhanced T1-weighted images. Acquisition sequence
(TR = 10,000 and TE = 100) was set to acquire 14.6-mm axial
sections through the brain using a 22-cm ﬁeld of view (FOV)
and 128 matrix. Once the tumor had been fully visualized, dif-
fusion-weighted imaging was performed in the transverse plane
by using a single-shot, spin-echo, echo-planar acquisition
sequence with diffusion gradient encoding in three orthogonal
directions at a low (b= 0), and a high (b= 1000 s/mm2)
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weighted images for the three orthogonal directions were com-
bined to calculate mean ADC map (5,24). The same study was
repeated 3 weeks after initiation of therapy and standard MRI
was performed to determine radiologic response 6 weeks after
completion of therapy.
2.3. Image registration
MR imaging data were transferred to a GE Advantage Work-
station (GE, Waukesha, USA). We deﬁned volumes-of-
interests (VOIs) by contouring the enhancing areas on T1 con-
trast enhanced images. Subsequent to contouring the tumors, a
geometric warping algorithm was used to warp the tumor vol-
umes from interval examinations onto the tumor volumes from
pretherapy images. As a result of registration, serial tumor vol-
umes, as determined by the contours, encompassed the same
three-dimensional space as the pretherapy tumor volume. Sub-
sequent to image registration, whole-tumor volume and mean
ADC value were assessed before and 3 weeks after treatment
initiation from the volumes-of-interests (VOIs.)
2.4. Interpretation and analysis of fDM
The functional diffusion map (fDM) was determined by calcu-
lating the difference between ADC value for each individual
voxel within the tumor at 3 weeks after initiation of therapy
and its corresponding pretherapy ADC value. The changes
were spatially displayed as three pseudocolor regions that were
overlayed on the anatomical postcontrast T1-weighted image.
Tumors were segmented into three regions based on a prede-
termined threshold (discussed later) as follows: voxels yielding
a signiﬁcant increase in ADC value were encoded in red (VR).
Blue voxels (VB) represented regions whose ADC values sig-
niﬁcantly decreased and the green voxels (VG) within the tu-
mor represented regions with non-signiﬁcant changes in
ADC values. The percentage of the tumor volumes within
these three regions (VR, VB, and VG), respectively as well as
the sum of percentages of the tumor volumes with signiﬁcant
change in diffusion values (VT), where VT = VR+ VB were
calculated. The volumes of these regions were also displayed as
red, blue and green data points on a (scatter plot) to allow for
quantitative assessment of overall changes in tumor ADC of
the entire tumor volume with the pretreatment ADC on the
x-axis and posttreatment ADC on the y-axis.
2.5. Evaluation of treatment response parameters
In order to evaluate the ability of fDM as an early imaging
biomarker for treatment response we correlated fDM data
gathered 3 weeks after initiation of therapy; when less than
half of the total therapeutic dose had been administered with
two biologically relevant endpoints; clinico-radiologic re-
sponse at 6 weeks after completion of therapy and overall pa-
tient survival. The percentage of change in whole-tumor
volume and the percentage of change in mean tumor ADC
were also measured at the same time point and correlated with
the clinico-radiologic response. The predictive value of the dif-
ferent response measures and their sensitivity and speciﬁcity
were compared using Receiver Operator Characteristic
(ROC) curve analysis. The clinico-radiologic response was
based on changes in tumor volume on T1 contrast enhancedMRI, steroid doses and neurological status of patients follow-
ing the world health organization criteria (25) and classiﬁed
patients into two groups: Responding group; were deﬁned as
patients whose tumors showed P50% decrease in tumor vol-
ume, on stable or decreased doses of steroids and neurologi-
cally stable or improved. Stable/non-responding group; were
deﬁned as patients whose tumors showed <50% decrease or
any increase in tumor volume. The percentage of change in tu-
mor volume was calculated by using the formula: %
DVN = (VN  V0)/V0 · 100, where V0 was tumor volume be-
fore therapy and VN was tumor volume on N time. The per-
centage of change in mean ADC values at 3 weeks after
initiation of therapy was calculated as follows: % DAD-
C3 = (ADC3  ADC0)/ADC0 · 100, where ADC0 was tumor
mean ADC value before therapy and ADC3 was tumor mean
ADC value at 3 weeks. Patients were followed up clinically
every 2 months, steroid doses were recorded before each scan
and at each follow-up visit.
2.6. Statistical analysis
Data was statistically analyzed using SPSS (Statistical Package
for Social Science) program version 13 for windows and results
were deﬁned as statistically signiﬁcant at P< 0.05. The thresh-
olds used for deﬁning signiﬁcant change within tumor voxels
were determined from co-registered data sets from all patients
that were correlated with a volume of interest within the nor-
mal contralateral cerebral hemisphere containing a range of
ADC values from normal gray and white matter by using lin-
ear least squares analysis and determined to be 52 · 105 mm2/
s. At 3 weeks after initiation of therapy, the quantiﬁed regional
volumes with signiﬁcant changes in diffusion values (VR, VB
and VT) within the tumor as well as the percentage of change
in whole-tumor volumes and mean ADC values were corre-
lated with patient’s standard clinico-radiologic response and
differences between response groups were determined by using
unpaired Student’s t test. The predictive values for treatment
response of VR, changes in whole-tumor volume and mean
tumor ADC were determined by using ROC curve analysis.
The area under the curve (AUC) represents the overall predic-
tive value. To optimize the sensitivity of fDM for prediction
and differentiation between the response groups a graphic plot
(box plots) was displayed to determine a VR threshold for
discrimination between responding versus stable/non-respond-
ing groups. The sensitivity, speciﬁcity, positive predictive value
[PPV], negative predictive value [NPV] and accuracy of the VR
threshold for determination of therapeutic response were
calculated as follows: Sensitivity = T (+ve)/T (+ve) + F
(ve); Speciﬁcity = T (ve)/T (ve) + F (+ve); [PPV] = T
(+ve)/T (+ve) + F (+ve); [NPV] = T (ve)/T (ve) + F
(ve) and Accuracy = T (+ve) + T (ve)/total [T = true,
F = false].
The log-rank test and Kaplan–Meier curves were used for
survival analyses of the two response groups.
3. Results
3.1. Patients characteristics
A total of 46 consecutive patients with primary brain tumors
were enrolled in this study. Patients’ ages ranged from 8 to
75 years (mean, 43 years). They were 24 males and 22 females.
444 B.A.M. Dessouky et al.On the basis of standard clinico-radiologic response criteria, 21
tumors (46%) were classiﬁed as responding (Fig. 1) and 25
(54%) as stable/non-responding (Figs. 2 and 3). Twenty pa-
tients (43%) had glioblastoma multiforme, 16 (35%) had
astrocytoma, 4 (9%) had germ cell tumors, 4 (9%) had prim-
itive neuroectodermal tumors and 2 (4%) had lymphoma con-
ﬁrmed by histology. Each patient had one brain tumor with a
total of 46 tumors analyzed. Fifteen (33%) tumors were fron-
tal, 14 (30%) were parietal, 11 (24%) were temporal and 6
(13%) were thalamic in location. Previous interventions in-
cluded surgery in 26 (56%) patients and biopsy in 20 (44%) pa-
tients. Prescribed therapies included chemotherapy for 16
(35%) patients, radiotherapy for 18 (39%) patients and com-
bined therapy for 12 (26%) patients. Mean baseline tumor vol-
ume was 36.9 mm3 and mean baseline ADC value was 77.7Fig. 1 MRI images of a male patient aged 32 years old with brain lym
brain shows an enhancing predominantly hyperintense left parietal tum
map (C) demonstrate slightly restricted diffusion. At 3 weeks afte
demonstrates no signiﬁcant changes in the size of the tumor, howeve
diffusivity within the tumor signifying underlying cell death. Based on t
weeks after initiation of therapy the tumor was scored as responding. F
the end of therapy (I) conﬁrmed fDM results with >50% decrease in t
the clinico-radiologic response criteria.(·105 mm2/s). At the time of analysis, 9 (20%) patients had
died of disease progression, whereas 37 (80%) were still alive.
Median follow-up for all patients was 12.8 months; median
overall survival was 21.9 months.
Analysis of the patient characteristics and baseline tumor
values revealed that there is no observable signiﬁcant differ-
ence between the responding and stable/non-responding
groups (P> 0.05). These data are summarized in Table 1.
3.2. Correlation between response parameters and
clinico-radiologic response
At 3 weeks after initiation of therapy we found that there were
no signiﬁcant changes (P> 0.05) observed in whole-tumor
volume in the group stratiﬁed as responding (1.3 ± 0.5%)phoma. Pretherapy axial-enhanced T1-weighted image (A) of the
or surrounded by a rim of edema. Axial DW image (B) and ADC
r initiation of therapy, axial-enhanced T1-weighted image (D)
r, axial DW image (E) and ADC map (F) demonstrate increased
he functional diffusion map image (G) and the scatter plot (H) at 3
ollow-up standard axial-enhanced T1-weighted image 6 weeks after
he tumor size and the patient was stratiﬁed as responding based on
Fig. 2 MRI images of a male patient aged 10 years old with brain astrocytoma. Pretherapy axial-enhanced T1-weighted image (A) of the
brain shows ring enhancing left parietal tumor surrounded by a rim of edema. Axial DW image (B) and ADC map (C) demonstrate that
the tumor is partly restricted in diffusion with other parts of increase diffusivity. At 3 weeks after initiation of therapy, axial-enhanced T1-
weighted image (D), axial DW image (E) and ADC map (F) demonstrate no signiﬁcant changes in the total volume of the tumor, however,
there is less restriction of diffusion with slight increase in diffusivity. Based on the functional diffusion map image (G) and the scatter plot
(H) at 3 weeks after initiation of therapy the tumor was scored as stable. Follow-up standard axial-enhanced T1-weighted image 6 weeks
after the end of therapy (I) conﬁrmed fDM results with no change in the tumor size and the patient was stratiﬁed as stable based on the
clinico-radiologic response criteria.
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non-responding (2.6 ± 0.8%) (Figs. 2(D) and 3(D)), as com-
pared to their baseline values. In addition, these changes did
not differentiate between both response groups (P> 0.05).
However, mean tumor ADC values were found to signiﬁcantly
increase from baseline values in both responding (9.5 ± 0.9%)
(Fig. 1(F)) and stable/non-responding (10.1 ± 0.7%) groups
(P< 0.05) (Figs. 2(F) and 3(F)). However, this increase did
not reach statistical signiﬁcance to differentiate between both
response groups (P> 0.05).
Analysis of the fDM regional volumes at 3 weeks (Figs. 1(G,
H), 2(G, H) and 3(G, H)) revealed that; responding tumors had
VR= 34.5 ± 8.9% (mean ± SD), VB = 5.1 ± 1.7% andVT= 39.6 ± 6.5%. While, stable/non-responding tumors
had VR= 8.8 ± 2.3%, VB = 7.7 ± 3.1% and VT = 9.9 ±
3.2. By using Student’s t test to quantify the statistical signiﬁ-
cance we found that VR and VT were signiﬁcantly greater in
responding tumors than in stable/non-responding tumors
(P< 0.001). On the other hand, VB values were not signiﬁ-
cantly different between responding tumors and stable/non-
responding tumors (P> 0.05). We found also that the VT
value for responding tumors was entirely derived from VR.
So, we focused on the VR value in our further analysis of tumor
response. Table 2 summarizes values of the different response
parameters used at 3 weeks after initiation of therapy to mea-
sure therapeutic response and their statistical signiﬁcance in
Fig. 3 MRI images of a male patient aged 56 years old with glioblastoma multiforme of the brain. Pretherapy axial-enhanced T1-
weighted image (A) of the brain shows a heterogeneously enhancing left fronto-parietal mass surrounded by marked edema. Axial DW
image (B) and ADC map (C) demonstrate markedly restricted diffusion suggestive of increased tumor cellularity. At 3 weeks after
initiation of therapy, axial-enhanced T1-weighted image (D), axial DW image (E) and ADC map (F) demonstrate no signiﬁcant changes in
the total volume of the tumor, with slightly increased diffusivity. Based on the functional diffusion map image (G) and the scatter plot (H)
at 3 weeks after initiation of therapy the tumor was scored as non-responding. Follow-up standard axial-enhanced T1-weighted image 6
weeks after the end of therapy (I) conﬁrmed fDM results with increase in the tumor size and the patient was stratiﬁed as non-responding
based on the clinico-radiologic response criteria.
446 B.A.M. Dessouky et al.differentiating patients’ response groups as correlated to the
standard clinico-radiologic response criteria determined 6
weeks after completion of therapy.
3.3. Predictive value of different response parameters
Further evaluation of the predictive value of change in
whole-tumor volume and change in mean ADC and fDM
(VR) at 3 weeks after initiation of therapy in determining
tumor response was performed by using ROC curve analy-
sis. We found that VR value was the most predictive oftumor response than changes in whole-tumor volume or
mean tumor ADC value measured at the same time point,
as exhibited by a greater area under the curve (AUC) for
VR (AUC= 0.96; sensitivity = 91%; speciﬁcity = 96%;
positive predictive value [PPV] = 90%; negative predictive
value [NPV] = 95%; P< 0.001) than either the change in
whole-tumor volume (AUC= 0.54; sensitivity = 23%; spec-
iﬁcity = 20%; PPV = 34%; NPV = 47%; P> 0.05) or
change in mean ADC (AUC= 0.62; sensitivity = 65%;
speciﬁcity = 55%; PPV = 67%; NPV = 59%; P> 0.05)
(Table 3).
Table 1 Pretherapy and therapy-related patient characteristics.
Variable All patients (n= 46) Clinicoradiologic response P value
Responding (n= 21) Stable/non-responding (n= 25)
Age, years >0.1a
Median (range) 43 (8–75) 45 (8–70) 48 (10–75)
Gender, No. (%) >0.5a
Male 24 (52%) 11 (24%) 13 (28%)
Female 22 (48%) 10 (22%) 12 (26%)
Tumor pathology, No. (%) >0.5a
Glioblastoma multiforme 20 (43%) 9 (20%) 11 (23%)
Astrocytoma 16 (35%) 7 (15%) 9 (20%)
Germ cell tumors 4 (9%) 3 (7%) 1 (2%)
Primitive neuroectodermal tumors 4 (9%) 1 (2%) 3 (7%)
Lymphoma 2 (4%) 1 (2%) 1 (2%)
Tumor location (No. (%) >0.5a
Frontal 15 (33%) 8 (18%) 7 (15%)
Parietal 14 (30%) 7 (15%) 7 (15%)
Temporal 11 (24%) 5 (11%) 6 (13%)
Thalamic 6 (13%) 3 (6.5%) 3 (6.5%)
Previous intervention >0.05a
Surgery 26 (56%) 13 (28%) 13 (28%)
Biopsy 20 (44%) 9 (20%) 11(24%)
Types of therapy, No. (%) >0.5a
Chemotherapy 16 (35%) 8 (17.5%) 8 (17.5%)
Radiation therapy 18 (39%) 8 (17.5%) 11(24%)
Combined therapy 12 (26%) 5 (11%) 6 (13%)
Mean baseline tumor volume (cm3) 36.9 36.7 37.1 >0.5b
Median baseline ADC (·105 mm2/s) 77.7 77.3 78 >0.5b
Abbreviation: ADC, apparent diffusion coefﬁcient.
P refers to the differences between the columns responding and stable/non-responding.
a Chi-square test.
b Student’s t test.
Table 2 Values of response parameters used at 3 weeks after initiation of therapy and their signiﬁcance in differentiating between
response groups.
Response measures at 3 weeks after initiation of therapy Standard clinico-radiologic response groups P value
Responding (n= 21) Stable/non-responding (n= 25)
Mean ± SD Mean ± SD
Percentage of change in whole-tumor volume 1.3 ± 0.5% 1.6 ± 0.8% >0.05
Percentage of change in mean tumor ADC 9.5 ± 0.9% 10.1 ± 0.7% >0.05
Percentage of fDM regional volumes
VR 34.5 ± 8.9% 2.2 ± 0.4% <0.001**
VB 5.1 ± 1.7% 7.7 ± 3.1% >0.05
VT 39.6 ± 6.5% 9.9 ± 3.2 <0.001**
Student’s t test.
P value >0.05, non-signiﬁcant.
** P value <0.001, highly signiﬁcant.
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In a trial to optimize fDM parameter values for early predic-
tion and discrimination between the response groups, we fo-
cused on VR region of the tumors and we observed the
range of ADC values within this region for each response
group in the box plot. We found that the minimum VR valueof the responding tumor (25.6%) was more than the maximum
VR values of stable/non-responding group (11.1%). The mid-
point between the minimum VR value for responding tumors
and maximum VR value for stable/non-responding tumors
was found to be 14.5% and was considered a threshold value
for discrimination between both response groups. Using a VR
value >14.5% allowed us to correctly identify all responding
Table 3 ROC analysis of different response measures for prediction of treatment response.
Variable at 3 weeks AUC Sensitivity (%) Speciﬁcity (%) PPV NPV P
fDM-VR 0.96 91 96 90 95 <0.001**
Change in volume 0.54 23 20 34 47 >0.05
Change in ADC 0.62 65 55 67 59 >0.05
Abbreviations: AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; ADC, apparent diffusion coefﬁcient;
fDM, functional diffusion map; VR, areas within the tumor with signiﬁcant increase in ADC values.
**P value <0.001, highly signiﬁcant.
448 B.A.M. Dessouky et al.tumors (true positive = 21, false positive = 0). However,
using a VR value <14.5% identify all stable/non-responding
(true negative = 25, false negative = 0). The sensitivity, spec-
iﬁcity, positive and negative predictive values and overall accu-
racy for deﬁning and discriminating responding from stable/
non-responding tumors at 3 weeks after initiation of therapy
were found to be 100% for all the patients based on VR
threshold value of 14.5%. The box plots (Fig. 4) summarize
the range of VR volumes of signiﬁcant increase in diffusion
values obtained from fDM for each of the patient-response
groups for all the patients.
3.5. Direct prediction of patient survival based on VR threshold
To assess the correlation of fDM analysis with patient sur-
vival, all 46 patients with 3-week data available were catego-
rized as either responding or stable/non-responding on the
basis of the VR threshold, as indicated above. As VR thresh-
old correctly identiﬁed all patients in both response groups.
So, prediction of patient survival using the VR threshold of
14.5% at 3 weeks after initiation of therapy had the same prog-
nostic value as the standard clinico-radiologic criteria used to
evaluate patient survival 6 weeks after the end of therapy. The
Kaplan–Meier curves revealed that non-responding tumors at
3 weeks by fDM greatly had a shorter survival (mean 8.7
months) compared to those with responding tumors (mean
35.6 months); **P< 0.001; log-rank test) (Fig. 5).Fig. 4 Box plot summarizing the regional volumes (percentage
of total) within the tumors that experienced signiﬁcantly increased
diffusion values (VR). Values depicted are the mean for each
group (lines through the boxes) with the upper and lower limits of
the box representing the range (75th and 25th percentile),
respectively. The error bars represent the 95th and the 5th
percentiles. The dots are the limits (maximum and minimum) of
the data range.4. Discussion
Imaging biomarkers have become valuable tools for the detec-
tion and characterization of brain tumors as well as for mon-
itoring the response to therapy (26). At present, comparison of
sequential magnetic resonance imaging (MRI) scans is the
method of choice for monitoring the response to therapy to
follow the shrinkage or continued growth of the tumor. How-
ever, it takes months before tumor size decreases or increases
to an extent that the change can be visualized clearly. Further-
more, some tumors fail to shrink or even increase in size after
treatment because of therapeutic-induced central necrosis and
not because of treatment failure (27–29).
Diffusion magnetic resonance imaging (DW-MRI) has
been used to assess therapy response in patients with brain
tumors (29–31). Parameters derived from DW-MRI are vali-
dated as imaging biomarkers because the acquisition is non-
invasive, does not require any exogenous contrast agents and
does not use ionizing radiation yet is quantitative and can be
obtained relatively rapidly, and is easily incorporated into
routine patient evaluations (6). The maximal diffusion change
preceded changes in tumor volume by weeks to months, sug-
gesting that the diffusion parameters could be useful as an
early predictor of therapeutic response in human brain tumors
(9). A new imaging analysis method that looks at individual
ADC voxels, rather than a composite view and was able to pre-
dict treatment response and which patients would live longer
was developed by researchers from the University of Michigan
Comprehensive Cancer Center (5). They called this special type
of diffusion MRI scan ‘‘functional diffusion map (fDM)’’. It is
a statistical method that prospectively compares heteroge-
neous ADC maps acquired post-initiation of therapy with
pretreatment ADC maps where the two image data sets are
co-registered and computationally analyzed to yield statistical
maps of ADC change as color overlays on anatomical images
and scatter plots of ADC change to determine tumor response
in patients with brain tumors when there would still be time to
adapt treatment based on early imaging biomarker readout if
it predicted insufﬁcient response to treatment (2,4,5,32).
Previously we had seen therapeutic-induced changes by
using mean ADC values in brain tumor patients (33). How-
ever, other recently published articles reported that, mean
ADC values were not as predictive as the fDM approach re-
ported because of the lack of sensitivity of changes in ADC
mean values in the presence of signiﬁcant cellular heterogene-
ity within the tumor mass. Different areas of tumor with
increasing and decreasing changes in diffusion would cancel
out, such that there would be no observed change in overall
mean ADC, which could account for a loss in its sensitivity
to differentiate responding from non-responding tumors
Fig. 5 Overall survival by log-rank test and Kaplan–Meier survival plot based on fDM stratiﬁcation 3 weeks from the start of treatment
where the blue curve (n= 21) represents patients with VR >14.5% and the red curve (n= 25) represents those with VR <14.5%.
Median survival was 8.7 versus 35.6 months, respectively (**P< 0.001; log-rank test).
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found to be lower in those patients with later progression of
disease than patients without evidence of residual disease.
Therefore, given the signiﬁcant tumor regression observed
after 2–3 weeks of treatment, the maximal fDM response
may have occurred earlier than the measurement interval eval-
uated (2,35). A similar phenomenon was observed in patients
treated with neoadjuvant chemoradiotherapy for rectal cancer
where DWI at 1 week identiﬁed a group of patients with a rise
in ADC who later had favorable pathologic features (necrosis
and negative surgical margins), whereas diffusion assessment
at 1 month demonstrated an overall decline in diffusion, which
was not prognostic and which the authors attributed to ﬁbrosis
(36,37). In addition, investigators at the University of Pennsyl-
vania recently obtained encouraging results with diffusion
MRI as early as 1 week into a course of chemoradiotherapy
for head and neck cancer with minimal volume changes (38).
The current study conﬁrms earlier work on patients with
primary malignant brain tumors (5). We found that there were
early changes in mean ADC values (P< 0.05) and fDM
parameters (VR and VT) (P< 0.001) at 3 weeks after initia-
tion of therapy; however, no signiﬁcant changes in whole-
tumor volumes (P> 0.05) were observed at the same time
point as compared to their baseline pretherapy values. The
changes quantiﬁed by mean ADC values observed in our study
at 3 weeks after initiation of therapy did not differentiate be-
tween responding and stable/non-responding tumors
(9.5 ± 0.9% versus 10.1 ± 0.7%; P> 0.05). A group of
investigators (2) in a previous article on brain gliomas conﬁrm
these observations, they found that, at the 3 weeks interval
mean ADC values of responding and stable/non-responding
tumors increased from baseline values (P< 0.001) with non-
signiﬁcant observable tumor shrinkage or growth found in
both responding and non-responding tumors (P= 0.005). An-
other group of researchers (4) had serially measured ADC val-
ues 1, 3 and 10 weeks from the start of treatment and had
found that, ADC values remained fairly constant over time
for the responding tumor although a gradual increase inADC was observed over time with the appearance of small re-
gions of high ADC (red) due to regional spontaneous necrosis
as tumors become large.
In our study, results obtained from 46 patients with pri-
mary malignant brain tumors revealed that, fDM images could
circumvent tumor heterogeneity by capturing areas of signiﬁ-
cantly increased diffusivity (VR; red voxels), areas of signiﬁ-
cantly restricted diffusion (VB; blue voxels) and areas of
unchanged diffusivity (VG; green voxels) and thus provides
full anatomic and spatial imaging information which allows
a visual comparison of regional changes in ADC between the
responding and stable/non-responding groups. This data can
also be presented in a scatter plot and percentages assigned
to the three deﬁned ADC regions, allowing quantitative assess-
ment of overall changes in tumor ADC values. The hypothesis
underlying this method that has been described in previous
articles (5,39) is that, diffusion-weighted images (DWI) that
measures water mobility is inversely related to cellularity. Den-
sely packed tumor cells due to rapid cellular proliferation hin-
der water movement to produce a low ADC, corresponding
with blue voxels. Water moves more freely and ADC increases
as the membranes of cells break down during a positive re-
sponse to therapy. ADC increases even further during massive
tumor cell necrosis and cell death, corresponding with red vox-
els. Histologic assessment of the different fDM regions (VR
and VB) on animal models with implanted tumors was per-
formed in a study by Lee et al. (40). Their data revealed that
VR correlated with a region of signiﬁcant treatment-induced
cell death. However, foci of tumor regions undergoing rapid
cellular proliferation were also detected by VB as regions of
greatly reduced water mobility, conﬁrmed by histology as focal
regions of high cell density along with high mitotic index. They
concluded that a dynamic shift in the overall tumor cytoarchi-
tecture toward a loss of cell density/membrane integrity oc-
curred following treatment.
Analysis of fDM in our study revealed that the regional vol-
ume of tumor with a signiﬁcant increase in diffusion (VR) as
well as the sum of regional tumor volumes with signiﬁcant
450 B.A.M. Dessouky et al.increase and decrease in ADC values (VT where,
VT = VR+ VB) were directly correlated with the standard
clinico-radiologic response and allowed us to differentiate be-
tween responding and stable/non-responding tumors
(P< 0.001). In contrast volumes within the tumor with
decreasing ADC (VB; blue voxels) could not differentiate be-
tween both response groups (P> 0.05). These ﬁndings were
similar to the results of previously published articles (4,5) on
patients with primary malignant brain tumors. They reported
that the percentage of tumor with signiﬁcantly increased
ADC values as assessed by the metric VR was associated with
disease control at 6 months (P< 0.05) with no signiﬁcant
association between the volume of tumor with decreasing
ADC (VB; blue voxels) and clinical progression. A more recent
study by Hamstra et al. (2) revealed that fDM could be used to
stratify patients as responsive or non-responsive to therapy as
early as 3 weeks into a 6- to a 7-week fractionated therapy
schedule.
Recently published articles by a group of researchers at
University of Michigan (2,4) found that analysis of ADC maps
by fDM was more sensitive to small differences in response
than whole-tumor volumes and mean ADC changes. In our
study the same results were obtained at 3 weeks into therapy
using ROC curve analysis as exhibited by a greater area under
the curve (AUC). For VR, AUC= 0.96 was greater than the
change in whole-tumor volume (AUC= 0.54) and change in
mean ADC (AUC= 0.62).
Optimization of fDM parameters for the quantiﬁcation of
early treatment response in patients with brain tumors was im-
proved by using a VR threshold of 14.5% based on analysis
and display of the range of VR values obtained at 3 weeks after
initiation of therapy on the Box plot. We found that instead of
waiting 6 weeks after completion of therapy we would use VR
threshold of 14.5% and we would correctly determine and dis-
criminate between both response groups exactly as the results
obtained from analysis of the standard clinico-radiologic re-
sponse criteria with sensitivity, speciﬁcity, positive and nega-
tive predictive values of 100%. These results were similar to
those obtained by Moffat et al. (5) who determined a threshold
of 14% for discrimination between response groups with sen-
sitivity, speciﬁcity, positive and negative predictive values of
100% for all their studied 20 patients based on fDM analysis.
Patient survival was considered the ‘‘gold standard’’ of
treatment efﬁcacy measures. Functional diffusion mapping
(fDM) was shown to be able to identify early patients who
are prone to have signiﬁcantly poorer survival and time-
to-progression from those patients who would have a much
more responsive outcome. As discussed previously, in our
study we found that the use of 3 weeks VR threshold of
14.5% as an early biomarker correctly identiﬁed all responding
and stable/non-responding groups of patients and discrimi-
nated them from each other, so we assumed that its prognostic
value as a determinant of patients survival was exactly the
same as the clinico-radiologic response criteria determined 6
weeks after completion of therapy. Our suggestion was con-
ﬁrmed by using the log-rank test and Kaplan–Meier curves
that revealed that patients with non-responding tumors at 3
weeks by fDM had a shorter survival (mean 8.7 months) com-
pared to those with non-responding tumors (mean 35.6
months); **P<0.001; log-rank test). These ﬁndings coincided
with others (2) who reported that the use of 3-week fDM-VR
as an early biomarker for survival provided response-basedprediction of patient survival and was at least as prognostic
as the Macdonald criteria at 10 weeks but was obtained 7–8
weeks earlier. In their study, patients identiﬁed by fDM as
responsive survived threes times longer than patients with pro-
gressive disease.5. Conclusions
We concluded that fDM provided early, reliable and unique
spatial and functional information that could be applied to
quantify treatment-induced changes, determine and discrimi-
nate between response groups as compared to the currently used
traditional response measures. It supplies the oncologists with
very useful clinical information during the course of treatment
that allows them to shift to an alternative therapy if the treat-
ment is unsuccessful, and target higher radiation doses to the re-
gions that are not responding. The quantiﬁed volumes with
signiﬁcant increase in diffusion values (VR; red voxels) within
the tumor as early as 3 weeks after initiation of therapy could
be used as surrogate endpoint an for direct prediction of patient
response and survival as equal as the standard clinico-radiologic
response determined 6 weeks after the end of therapy.
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